Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Fundamental Analysis

NASDAQ:CLYM - US28658R1068 - Common Stock

2.3 USD
+0.01 (+0.66%)
Last: 8/28/2025, 8:01:15 PM
2.31 USD
+0.01 (+0.43%)
After Hours: 8/28/2025, 8:01:15 PM
Fundamental Rating

3

Taking everything into account, CLYM scores 3 out of 10 in our fundamental rating. CLYM was compared to 547 industry peers in the Biotechnology industry. CLYM has a great financial health rating, but its profitability evaluates not so good. CLYM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLYM has reported negative net income.
In the past year CLYM has reported a negative cash flow from operations.
In the past 5 years CLYM always reported negative net income.
In the past 5 years CLYM always reported negative operating cash flow.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CLYM has a Return On Assets of -24.30%. This is in the better half of the industry: CLYM outperforms 73.67% of its industry peers.
The Return On Equity of CLYM (-25.17%) is better than 80.99% of its industry peers.
Industry RankSector Rank
ROA -24.3%
ROE -25.17%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLYM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLYM has more shares outstanding
CLYM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 11.74 indicates that CLYM is not in any danger for bankruptcy at the moment.
CLYM's Altman-Z score of 11.74 is amongst the best of the industry. CLYM outperforms 87.57% of its industry peers.
There is no outstanding debt for CLYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.74
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 14.08 indicates that CLYM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 14.08, CLYM belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
CLYM has a Quick Ratio of 14.08. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
CLYM has a better Quick ratio (14.08) than 88.67% of its industry peers.
Industry RankSector Rank
Current Ratio 14.08
Quick Ratio 14.08
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

CLYM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.71%, which is quite impressive.
EPS 1Y (TTM)67.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.51% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.71%
EPS Next 2Y23.51%
EPS Next 3Y11.51%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.51%
EPS Next 3Y11.51%

More info and screens

0

5. Dividend

5.1 Amount

CLYM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLIMB BIO INC

NASDAQ:CLYM (8/28/2025, 8:01:15 PM)

After market: 2.31 +0.01 (+0.43%)

2.3

+0.01 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)N/A N/A
Inst Owners84.99%
Inst Owner ChangeN/A
Ins Owners0.37%
Ins Owner Change55.49%
Market Cap155.85M
Analysts87.5
Price Target9.18 (299.13%)
Short Float %2.11%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.75%
Min EPS beat(2)-102.61%
Max EPS beat(2)31.11%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10%
PT rev (3m)-10%
EPS NQ rev (1m)24.36%
EPS NQ rev (3m)7.81%
EPS NY rev (1m)17.5%
EPS NY rev (3m)16.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS2.74
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.3%
ROE -25.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.08
Quick Ratio 14.08
Altman-Z 11.74
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.91%
EPS Next Y52.71%
EPS Next 2Y23.51%
EPS Next 3Y11.51%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-240.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.9%
OCF growth 3YN/A
OCF growth 5YN/A